A team of researchers has developed an antiviral inhibitor that is active against several coronaviruses, including those causing the common cold and SARS. The compound targets the main protease enzyme, which is crucial for viral replication, and shows promise as a potential treatment for coronavirus-related diseases.
A novel coronavirus, HCoV-NL63, is strongly associated with croup in children under three years old. The study found that 43% of patients with high viral load and no co-infection had croup, compared to 6% of those without the virus.
A new coronavirus has been found in children with symptoms of Kawasaki disease, a condition that also affects the lungs. The virus was detected in 73% of Kawasaki patients but only 5% of healthy children.
Researchers have successfully developed a human SARS immunisation in animal studies, showing that monkeys vaccinated with the SARS vaccine had antibodies to the virus and no evidence of viral shedding. In contrast, control group monkeys without vaccination showed significant viral shedding after infection.
Researchers believe SARS evolved from a rare recombination of mammalian and avian viruses, enabling it to evade human immune systems. The study sheds light on the evolutionary history of SARS, which may hold clues to designing effective treatments and vaccines.
The article reports on the release of the first peer-reviewed SARS genome sequence, confirming a new variety of coronavirus and providing insights into the virus's molecular components. The genomic sequence is expected to aid in the diagnosis, treatment, and prevention of SARS.
A new human coronavirus has been identified as a likely cause of SARS, according to a study published in The Lancet. The virus was found in 90% of patients with SARS, but its genetic analysis suggests it may have originated from animals.